About Company
QED Therapeutics is a biotechnology company focused on developing targeted therapies for rare and genetic diseases, particularly in the field of precision oncology. Their research is centered on using cutting-edge science to discover and develop treatments for patients with serious unmet medical needs. QED Therapeutics works to advance the understanding of genetic mutations and their role in disease progression, aiming to deliver innovative therapies that provide more effective and personalized treatment options. Their commitment to scientific excellence and patient-centric care drives their pursuit of new therapies to improve the lives of those with rare diseases.
BridgeBio Pharma is a biotechnology company focused on developing and commercializing medicines for genetic diseases and cancers with a high unmet medical need. The company leverages its expertise in molecular biology and drug discovery to identify novel treatments, primarily for rare and orphan diseases. BridgeBio's pipeline includes targeted therapies designed to address the underlying genetic causes of diseases, aiming for transformative outcomes for patients. By utilizing a portfolio of promising drug candidates, the company is dedicated to improving lives through scientific innovation and rigorous clinical development.